Business
Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy
All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value
About this update from Xenon Pharmaceuticals Inc.
[{"type":"text","content":"All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of","length":149,"tagName":"div"}]